GlobeNewswire·Nov 10, 2026, 1:24 PM ET

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology

69.2% of cutaneous sarcoidosis patients receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin by Week 16 versus 0% on placebo
Improvements in skin disease activity were evident as early as Week 4 & increased through Week 16
Brepocitinib 45 mg resulted in a mean CSAMI-A score reduction of 22.3 points compared to 0.7 points for placebo
76.9% of the 45 mg group achieved at least 50% improvement in skin disease activity compared to 0% on placebo
100% of the 45 mg group achieved a 10-point reduction in CSAMI-A compared to 14.3% on placebo
61.5% of the 45 mg group achieved low residual skin disease activity (CSAMI-A < 5) versus 0% on placebo
Participants on brepocitinib 45 mg reported significant improvements in skin-related quality of life with a mean Skindex-16 increase of 23.5 points
No serious adverse events occurred during the 16-week study period
Findings from this Phase 2 BEACON study will be presented by Dr. Misha Rosenbach at ACR Convergence 2026
The ongoing Phase 3 BEACON+ study is evaluating brepocitinib 45 mg with topline data expected in calendar year 2028
No FDA-approved therapies currently exist for cutaneous sarcoidosis despite its potential to cause permanent scarring & tissue destruction